JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8232 Nilotinib(AMN-107)
1 Citation

Target: Bcr-Abl

Summary: Bcr-Abl kinase inhibitor,selective

≥26.5 mg/mL
A8249 SB 431542
2 Citation

Summary: ALK inhibitor
A2149 Bosutinib (SKI-606)
1 Citation

Target: Bcr-Abl|Src

Summary: Potent Abl/Src kinases

≥26.5 mg/mL
A1670 Enzastaurin (LY317615)
2 Citation

Target: PKC

Summary: PKC beta inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥8.59 mg/mL
A1352 Zoledronic Acid

Target: Farnesyl Diphosphate Synthases

Summary: Potent nitrogen-containing bisphosphonates

insoluble in DMSO; insoluble in H2O; insoluble in EtOH
A8348 LY2157299
2 Citation

Summary: TGF-βR1 inhibitor,potent and selective

insoluble in H2O; ≥18.45 mg/mL
A8345 PF-562271 HCl

Target: FAK|Pyk2

Summary: FAK/Pyk2 inhibitor

≥26.35 mg/mL
A8341 Go 6976

Target: PKC

Summary: PKCα/PKCβ1 inhibitor

≥15.77 mg/mL
B1404 DCC-2036 (Rebastinib)

Target: FLT3|Bcr-Abl|Tie-2|KDR

Summary: Bcr-Abl inhibitor

≥27.7 mg/mL
B2191 Dequalinium Chloride

Target: PKC|Calcium-Activated Potassium (KCa) Channels

Summary: anti-tumor agent and PKC inhibitor

insoluble in H2O; insoluble in ETOH; insoluble in DMSO